• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pharmaceuticals

Eli Lilly has positive once-weekly insulin data

September 5, 2024 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) today announced positive results from phase 3 clinical trials evaluating its once-weekly insulin efsitora alfa. The Indianapolis-based pharmaceutical giant evaluated its once-weekly insulin in insulin-naïve adults in the QWINT-1 study. These adults have type 2 diabetes and are using basal insulin for the first time. Additionally, Eli Lilly’s QWINT-3 trial looked at […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Pharmaceuticals Tagged With: Eli Lilly, Eli Lilly & Co.

Aptar Group’s Unidose system to deliver neffy nasal epinephrine

August 16, 2024 By Sean Whooley

ARS Pharmaceuticals neffy nasal epinephrine

Aptar announced today that its Unidose liquid system received FDA approval to deliver ARS Pharmaceuticals’ neffy (epinephrine nasal spray). ARS won FDA approval last week for neffy as an emergency treatment for patients with Type I allergic reactions, including anaphylaxis. It marked a major innovation in epinephrine delivery as the first and only needle-free treatment […]

Filed Under: Business/Financial News, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: aptarpharma, arspharmaceuticals

ARS Pharmaceuticals wins first FDA approval for needle-free, nasal epinephrine

August 12, 2024 By Sean Whooley

ARS Pharmaceuticals neffy nasal epinephrine

ARS Pharmaceuticals (Nasdaq:SRPY) announced that it received FDA approval for its neffy (epinephrine nasal spray) 2 mg for treating of Type I allergic reactions. Approval includes the treatment of anaphylaxis, with the indication covering adults and children who weigh ≥30 kg (66 lbs.). It marks a major innovation in epinephrine delivery as the first and […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: arspharmaceuticals, FDA

FDA approves first opioid overdose reversal auto-injector from Purdue Pharma

August 8, 2024 By Sean Whooley

Purdue Pharma Logo

Purdue Pharma announced that the FDA approved its new drug application (NDA) for the Zurnai (nalmefene injection) auto-injector. The single-dose auto-injector delivers 1.5 mg of nalmefene hydrochloride per actuation. It marks the approved first nalmefene hydrochloride auto-injector for the emergency treatment of known or suspected opioid overdose. The agency approved the first nasal spray formulation […]

Filed Under: Auto-injectors, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: FDA, purduepharma

This simple, needle-free COVID vaccination device might stop transmission

August 7, 2024 By Jim Hammerand

“Finally,” many of us thought when we received our first jabs to vaccinate us against COVID-19 back in 2020 and 2021. Nearly four years later, COVID is still surging, constantly mutating to create new variants that evade our immunity from prior infections and the latest vaccines. And if the immediate and long-term harm from SARS-CoV-2 […]

Filed Under: Pharmaceuticals, Research & Development Tagged With: Bharat Biotech International, Washington University in St. Louis

FDA says Alcyone Therapeutics can continue study of drug delivery implant

July 31, 2024 By Sean Whooley

Alcyone Therapeutics Logo

Alcyone Therapeutics announced today that the FDA approved continued enrollment in a study of its ThecaFlex DRx drug delivery system. The company can continue enrolling in the PIERRE FDA investigational device exemption study for the implantable medical device. It evaluates the system, comprised of a subcutaneous port and intrathecal catheter system. This system provides chronic […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Orthopedics, Pharmaceuticals Tagged With: Alcyone Lifesciences, Alcyone Therapeutics, FDA

FDA concerns push Novo Nordisk once-weekly insulin timeline beyond 2024

July 11, 2024 By Sean Whooley

Novo Nordisk

Novo Nordisk announced that the FDA issued a Complete Response Letter (CRL) related to its once-weekly insulin submission. In the CRL, the FDA made requests for Novo Nordisk to complete before it can complete its review of a Biologics License Application (BLA). As a result, the insulin maker said it does not expect to fulfill […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: FDA, Novo Nordisk

Roche, Genentech to reintroduce drug-eluting eye implant in U.S. following 2022 recall

July 8, 2024 By Sean Whooley

Genentech Susvimo Implant Image 1 For Media

Roche subsidiary Genentech today reintroduced its Susvimo therapy for delivery via ocular implant in the U.S. following a recall. The FDA approved a post-approval supplement to Susvimo’s Biologics License Application (BLA). Approval reflects component-level updates made to the ocular implant and refill needle. Roche now plans to work to make Susvimo available in the U.S. […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: Genentech, Roche

Biora Therapeutics has positive oral drug delivery device data for treating ulcerative colitis

July 2, 2024 By Sean Whooley

Biora Therapeutics NaviCap oral drug delivery

Biora Therapeutics shared positive topline results from a trial of its orally administered drug-device combination for treating ulcerative colitis (UC). BT-600, a proprietary liquid formulation of tofacitinib, is delivered directly to the colon using Biora’s ingestible NaviCap device. Biora designed NaviCap to improve patient outcomes by enabling therapeutic delivery directly to the site of the […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Biora Therapeutics

Koru Medical gets regulatory nod in Japan for FreedomEdge drug delivery system

July 2, 2024 By Sean Whooley

Koru Medical FreedomEdge infusion system

Koru Medical Systems (Nasdaq:KRMD) announced today that it received regulatory clearance in Japan for its FreedomEdge infusion system. Clearance covers the delivery of multiple drugs, including CSL Behring’s Hizentra subcutaneous immunoglobulin (SCIg), Takeda Pharmaceutical’s Cuvitru SCIg and Sobi’s Aspaveli paroxysmal nocturnal hemoglobinuria (PNH). FreedomEdge offers the convenient and efficient administration of large-volume subcutaneous therapies at […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Regulatory/Compliance, Technology Tagged With: Koru Medical Systems

  • « Go to Previous Page
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Interim pages omitted …
  • Page 206
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS